160 related articles for article (PubMed ID: 37386935)
1. Restrictive Versus Permissive Use of Broad-spectrum Antibiotics in Patients Receiving Allogeneic Stem Cell Transplantation and With Early Fever Due to Cytokine Release Syndrome: Evidence for Beneficial Microbiota Protection Without Increase in Infectious Complications.
Weber D; Hiergeist A; Weber M; Ghimire S; Salzberger B; Wolff D; Poeck H; Gessner A; Edinger M; Herr W; Meedt E; Holler E
Clin Infect Dis; 2023 Nov; 77(10):1432-1439. PubMed ID: 37386935
[TBL] [Abstract][Full Text] [Related]
2. Metagenomic analysis of the stool microbiome in patients receiving allogeneic stem cell transplantation: loss of diversity is associated with use of systemic antibiotics and more pronounced in gastrointestinal graft-versus-host disease.
Holler E; Butzhammer P; Schmid K; Hundsrucker C; Koestler J; Peter K; Zhu W; Sporrer D; Hehlgans T; Kreutz M; Holler B; Wolff D; Edinger M; Andreesen R; Levine JE; Ferrara JL; Gessner A; Spang R; Oefner PJ
Biol Blood Marrow Transplant; 2014 May; 20(5):640-5. PubMed ID: 24492144
[TBL] [Abstract][Full Text] [Related]
3. Detrimental Effect of Broad-spectrum Antibiotics on Intestinal Microbiome Diversity in Patients After Allogeneic Stem Cell Transplantation: Lack of Commensal Sparing Antibiotics.
Weber D; Hiergeist A; Weber M; Dettmer K; Wolff D; Hahn J; Herr W; Gessner A; Holler E
Clin Infect Dis; 2019 Apr; 68(8):1303-1310. PubMed ID: 30124813
[TBL] [Abstract][Full Text] [Related]
4. The impact of intestinal microbiota in antithymocyte globulin-based myeloablative allogeneic hematopoietic cell transplantation.
Gu Z; Xiong Q; Wang L; Wang L; Li F; Hou C; Dou L; Zhu B; Liu D
Cancer; 2022 Apr; 128(7):1402-1410. PubMed ID: 35077579
[TBL] [Abstract][Full Text] [Related]
5. Microbiota Disruption Induced by Early Use of Broad-Spectrum Antibiotics Is an Independent Risk Factor of Outcome after Allogeneic Stem Cell Transplantation.
Weber D; Jenq RR; Peled JU; Taur Y; Hiergeist A; Koestler J; Dettmer K; Weber M; Wolff D; Hahn J; Pamer EG; Herr W; Gessner A; Oefner PJ; van den Brink MRM; Holler E
Biol Blood Marrow Transplant; 2017 May; 23(5):845-852. PubMed ID: 28232086
[TBL] [Abstract][Full Text] [Related]
6. Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults.
Theurich S; Fischmann H; Shimabukuro-Vornhagen A; Chemnitz JM; Holtick U; Scheid C; Skoetz N; von Bergwelt-Baildon M
Cochrane Database Syst Rev; 2012 Sep; (9):CD009159. PubMed ID: 22972135
[TBL] [Abstract][Full Text] [Related]
7. [Gut microbiota and graft-versus-host disease: broad-spectrum antibiotic use increases post-allogeneic hematopoietic stem cell transplant graft-versus-host disease-related mortality].
Shono Y
Rinsho Ketsueki; 2017; 58(7):835-842. PubMed ID: 28781282
[TBL] [Abstract][Full Text] [Related]
8. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
[TBL] [Abstract][Full Text] [Related]
9. Cytokine Release Syndrome during Antithymocyte Globulin/Anti-T Lymphocyte Globulin Serotherapy for Graft-versus-Host Disease Prophylaxis before Allogeneic Hematopoietic Stem Cell Transplantation: Incidence and Early Clinical Impact According to American Society of Transplantation and Cellular Therapy Grading Criteria.
Knaus HA; Rottner T; Baumann CK; Cserna J; Mitterbauer M; Schulenburg A; Rabitsch W; Wohlfarth P
Transplant Cell Ther; 2022 May; 28(5):260.e1-260.e9. PubMed ID: 35217212
[TBL] [Abstract][Full Text] [Related]
10. Prolonged Suppression of Butyrate-Producing Bacteria Is Associated With Acute Gastrointestinal Graft-vs-Host Disease and Transplantation-Related Mortality After Allogeneic Stem Cell Transplantation.
Meedt E; Hiergeist A; Gessner A; Dettmer K; Liebisch G; Ghimire S; Poeck H; Edinger M; Wolff D; Herr W; Holler E; Weber D
Clin Infect Dis; 2022 Mar; 74(4):614-621. PubMed ID: 34043764
[TBL] [Abstract][Full Text] [Related]
11. Alteration of the Intestinal Microbiota by Broad-Spectrum Antibiotic Use Correlates with the Occurrence of Intestinal Graft-versus-Host Disease.
Lee SE; Lim JY; Ryu DB; Kim TW; Park SS; Jeon YW; Yoon JH; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Cho SG; Kim DW; Lee JW; Kim CS; Shin DM; Min CK
Biol Blood Marrow Transplant; 2019 Oct; 25(10):1933-1943. PubMed ID: 31195137
[TBL] [Abstract][Full Text] [Related]
12. Beneficial Role of Low-Dose Antithymocyte Globulin in Unrelated Stem Cell Transplantation for Adult Patients with Acquired Severe Aplastic Anemia: Reduction of Graft-versus-Host Disease and Improvement of Graft-versus-Host Disease-Free, Failure-Free Survival Rate.
Park SS; Kwak DH; Jeon YW; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Min WS; Lee JW
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1498-1508. PubMed ID: 28554856
[TBL] [Abstract][Full Text] [Related]
13. Post-Transplant Cyclophosphamide Combined with Anti-Thymocyte Globulin as Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome.
Alanazi W; Chen S; Lipton JH; Kim DD; Viswabandya A; Kumar R; Lam W; Law AD; Al-Shaibani Z; Mattsson J; Michelis FV
Acta Haematol; 2021; 144(1):66-73. PubMed ID: 32428903
[TBL] [Abstract][Full Text] [Related]
14. The association between the incidence of intestinal graft-vs-host disease and antibiotic use after allogeneic hematopoietic stem cell transplantation.
Hidaka D; Hayase E; Shiratori S; Hasegawa Y; Ishio T; Tateno T; Okada K; Goto H; Sugita J; Onozawa M; Nakagawa M; Kahata K; Endo T; Hashimoto D; Teshima T
Clin Transplant; 2018 Sep; 32(9):e13361. PubMed ID: 30054935
[TBL] [Abstract][Full Text] [Related]
15. Protective Effect of Intestinal Blautia Against Neutropenic Fever in Allogeneic Transplant Recipients.
Rashidi A; Peled JU; Ebadi M; Rehman TU; Elhusseini H; Marcello LT; Halaweish H; Kaiser T; Holtan SG; Khoruts A; Weisdorf DJ; Staley C
Clin Infect Dis; 2022 Nov; 75(11):1912-1920. PubMed ID: 35435976
[TBL] [Abstract][Full Text] [Related]
16. Post-transplant cyclophosphamide combined with anti-thymocyte globulin for graft-vs-host disease prophylaxis improves survival and lowers non-relapse mortality in older patients undergoing allogeneic hematopoietic cell transplantation.
Pasic I; Lipton JH; Kim DD; Viswabandya A; Kumar R; Lam W; Law AD; Mattsson J; Michelis FV
Ann Hematol; 2020 Jun; 99(6):1377-1387. PubMed ID: 32382774
[TBL] [Abstract][Full Text] [Related]
17. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic hematopoietic cell transplantation, the microbiome, and graft-versus-host disease.
van Lier YF; Vos J; Blom B; Hazenberg MD
Gut Microbes; 2023; 15(1):2178805. PubMed ID: 36794370
[TBL] [Abstract][Full Text] [Related]
19. Low-dose anti-thymocyte globulin reduce severe acute and chronic graft-versus-host disease after allogeneic stem cell transplantation.
Imataki O; Matsumoto K; Uemura M
J Cancer Res Clin Oncol; 2017 Apr; 143(4):709-715. PubMed ID: 28062916
[TBL] [Abstract][Full Text] [Related]
20. Incidence and risk factor of hemorrhagic cystitis after allogeneic transplantation with fludarabine, busulfan, and anti-thymocyte globulin myeloablative conditioning.
Lam W; Storek J; Li H; Geddes M; Daly A
Transpl Infect Dis; 2017 Jun; 19(3):. PubMed ID: 28199755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
